359804-46-9

Basic information

• Product Name: 5-((4-methoxybenzyl)thio)-2-nitroaniline
• Synonyms: 5-((4-methoxybenzyl)thio)-2-nitroaniline
• CAS NO: 359804-46-9
• Molecular Weight: 290.343
• Mol File: 359804-46-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 5-((4-methoxybenzyl)thio)-2-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((4-methoxybenzyl)thio)-2-nitroaniline(359804-46-9)
• EPA Substance Registry System: 5-((4-methoxybenzyl)thio)-2-nitroaniline(359804-46-9)

Safety Data

• Hazardous Substances Data: 359804-46-9(Hazardous Substances Data)

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 6258-60-2 p-methoxybenzylmercaptan 

Downstream Products

• 1001076-51-2 C₂₀H₂₄N₂O₄S 
• 1001076-56-7 C₂₀H₂₄N₂O₄S 
• 1001076-91-0 C₁₉H₁₉N₃O₄S 
• 1602770-10-4 N-(5-(4-methoxybenzylthio)-2-nitrophenyl)acetamide 
• 1001076-92-1 hexane 
• 1001077-24-2 C₁₉H₂₂N₂OS 
• 1010115-63-5 C₁₉H₂₈N₂OS 
• 1010115-62-4 C₂₇H₃₆N₂O₂S 
• 1010115-61-3 C₂₇H₃₈N₂O₃S 
• 1010115-37-3 C₂₃H₂₇F₃N₂OS 
• 1001077-09-3 C₂₃H₂₉F₃N₂O₂S 
• 1001076-93-2 hexane 
• 1001076-58-9 C₂₅H₃₂N₂OS 
• 1001076-57-8 C₂₀H₂₄N₂OS 

Relevant articles and documents

Synthesis and: In vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands

Cannabinoid type 2 receptor (CB2) is up-regulated on activated microglial cells and can potentially be used as a biomarker for PET-imaging of neuroinflammation. In this study the synthesis and pharmacological evaluation of novel fluorinated pyridyl and et

BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP

The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.

FLUOROALKYL SUBSTITUTED BENZIMIDAZOLE CANNABINOID AGONISTS

The present invention is related to benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the trea